USPTO serial 88614061
DIRECTMX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 1, 2020
- Examiner
- LE, MARGARET
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with DIRECTMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy P. Naill
Timothy P. Naill REINHART BOERNER VAN DEUREN P.C.2215 PERRYGREEN WAYROCKFORD, IL 61107UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in industry; Biological preparations for use in science; Carriers for biologically active compounds; Biological substances, materials, preparations and elements for scientific and industrial use in vivo and in vitro; Chemical substances, chemical materials and chemical preparations, and natural elements for scientific and industrial use in vivo and in vitro; biological materials for use in industry and science; Chemical substances, materials, preparations and elements for cosmetic preparations; Biological substances, materials, preparations and elements for cosmetic preparations; Lipid nanoparticles for use in industry and science; Lipid nanoparticles comprising protein for use in industry and science; Saposin-lipid nanoparticles for use in industry and science | ACTIVE | — |
| 005 | Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases; Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in non-human animals; Biological reagents for medical use; Biological reagents for veterinary use; Carriers for pharmaceutical, medical, veterinary or diagnostic compounds; Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in humans and non-human animals and for use in a diagnostic method; Medicinal preparations and substances for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in humans and non-human animals; Veterinary vaccines; Human vaccine preparations; Lipid nanoparticles for medicinal, diagnostic or pharmaceutical purposes; Lipid nanoparticles comprising protein for medical, diagnostic or pharmaceutical purposes; Saposin-lipid nanoparticles for medical, diagnostic or pharmaceutical purposes | ACTIVE | — |
| 040 | Treatment of cells and/or viruses and/or biological membranes to obtain carriers for biologically active, pharmaceutical or diagnostic compounds; Conversion of cells and/or viruses and/or biological membranes into biochemical preparations; Custom manufacturing of lipid nanoparticles in particular of lipid nanoparticles comprising protein or Saposin-lipid nanoparticles; Processing of cells and/or viruses and/or biological membranes for third parties | ACTIVE | — |
| 042 | Biological laboratory services; Biochemistry consultancy; Consulting services in the field of lipid nanoparticles in particular in the field of lipid nanoparticles comprising protein or Saposin-lipid nanoparticles | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SALIPRO BIOTECH AB
- Other trademarks owned by SALIPRO BIOTECH AB
- Other trademarks owned by SALIPRO BIOTECH AB
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named DIRECTMX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 1, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Dec 1, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 15, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 15, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 26, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 9, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 9, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 9, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 9, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 9, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 24, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 24, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 24, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 15, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 15, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 15, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jun 4, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 19, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 13, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 20, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 16, 2019 | NWAP | NEW APPLICATION ENTERED | — |